Aberrant alteration of follicular T helper cells in ulcerative colitis patients and its correlations with interleukin-21 and B cell subsets

Quohui Xue, PhD, Yao Zhong, MD, Lin Hua, MD, Meijun Zhong, MD, Xiaofeng Liu, BS, Xueli Chen, BS, Dian Gao, PhD, Nanjin Zhou, MD

Abstract

Patients with ulcerative colitis (UC) are at increased risk of developing colitis-associated colon cancer. Accumulating evidence suggests that follicular T helper (TFH) cells play a crucial role in the pathogenic process of autoimmune diseases. However, little is known about the role of TFH cells in the development of UC. To investigate the role of TFH cells in the development of UC, the number of TFH cells, the level of interleukin-21 (IL-21), the numbers of B cell subsets, and clinical parameters were detected in peripheral blood from 31 UC patients and 29 healthy controls. TFH cells and the level of IL-21 were significantly higher in UC patients than in the healthy controls. A positive correlation between TFH and IL-21 cells was found in UC patients. Moreover, aberrant frequencies of different subsets of B cells were observed in UC patients, and a positive correlation was found between CD38+CD19+ B cells and TFH cells and between CD68+CD19+ B cells and TFH cells. A high number of TFH cells were positively associated with Mayo score, serum C-reactive protein (CRP) and serum IgG in UC patients. Our data indicate that TFH cells and IL-21 are involved in the pathogenesis of UC.

Abbreviations: CAC = colon cancer, CD = Crohn’s disease, CRP = C-reactive protein, CXCR5 = C-X-C chemokine receptor type 5, DCs = dendritic cells, ELISA = enzyme-linked immunosorbent assay, ESR = erythrocyte sedimentation rate; GC = germinal centres, HC = healthy control, IBD = inflammatory bowel diseases, ICOS = inducible T-cell costimulator, IL = interleukin, NK cell = natural killer cell, PBMCs = peripheral blood mononuclear cells, RA = rheumatoid arthritis, RORγt = RAR-related orphan receptor gamma 2, SLE = systemic lupus erythematosus, SS = Sjögren’s syndrome, TFH = follicular T helper cells, TN = T helper cells, UC = ulcerative colitis.

Keywords: biomarker, follicular T helper cells, interleukin-21, ulcerative colitis

1. Introduction

Ulcerative colitis (UC) is one of the major forms of inflammatory bowel diseases (IBDs) in humans. Patients with ulcerative colitis have an increased risk of developing colon cancer (CAC),[1] and the risk rank is correlated with the duration and severity of the disease.[2] Although the etiology and pathogenic process of UC remain unclarified, recent studies suggest that the abnormal interplay between T cells and other immune and nonimmune cells is pivotal in driving pathologic processes of UC,[3,4] and T cell-derived cytokines are essential mediators of this cross-talk.[5]

The primary function of CD4+ TFH cells is to help the immune system fight infections. This function relies on the flexibility of naive CD4+ T cells, which differentiate into diverse TFH cell subsets with specialized effector function by distinct pathogen conditions. Under pathogenic conditions, aberrant levels of some cytokines promote the differentiation or function of specific effector T cell populations, which may unbalance the intestinal immune system and bring about a state of inflammation.[6] Moreover, the differentiation of B cells to antibody-secreting cells requires the assistance of TFH cell subsets, and then, the production of neutralizing antibodies provides lasting protection against most pathogen infections. In this interplay, follicular T helper (TFH) cells play a key role in the development of antigen-specific B cells.[7-8]

TFH cells are a specialized subset of CD4+ helper T cells located in germinal centres (GC) and are classically identified by their combined surface expression of inducible costimulator (ICOS), C-X-C chemokine receptor type 5 (CXCR5), and programmed cell death-1 (PD-1), as well as the intracellular expression of the transcription factor Bcl-6.[12] Notably, as shown recently, TFH cells secrete IL-21 to modulate both humoral and cell-mediated immune responses in different murine and human autoimmune diseases, including systemic lupus erythematosus (SLE), Sjögren’s syndrome (SS), and rheumatoid arthritis (RA).[11-13] However, little is known about how these different subsets of TFH cells act in UC patients and whether TFH cells are involved in the pathogenesis of UC.
IL-21 is a pleiotropic cytokine synthesized not only by TH₁ cells but also by TH₁1 and TH₁7 cells in the germinal centres.[16] IL-21 regulates the activation, proliferation, and survival of both CD4⁺ T cells and B cells, as well as the functional activity of CD8⁺ T cells and NK cells, and it limits the differentiation of inducible regulatory T cell.[16] Clearly, IL-21 is involved in the regulation of central functions of the immune system. Elevated IL-21 has been observed in the gut of patients with IBD, especially in Crohn’s disease (CD), which is thought to be caused by an exaggerated Th1 response against the luminal flora.[5,17] whereas there are limited data about IL-21 in patients with UC.

In this context, to further investigate the potential relationship between the TH₁ cells and clinical parameters of UC, we measured the proportions of circulating TH₁ cells and activated B cells in patients with UC compared to those of healthy controls and analysed the correlation between the population ratio of TH₁ cells and the IL-21 level, the proportion of B cell subsets, Mayo score, and other clinical-pathological features.

2. Method and materials

2.1. Patients

Patients gave informed consent for their samples to be analyzed in accordance with the Declaration of Helsinki. The study was approved by the Human Ethics Committee of Jiujiang First People’s Hospital (Jiangxi, China). A total of 31 untreated UC patients and 29 sex- and age-matched healthy controls were recruited from our hospital. The diagnosis and Mayo score of 31 UC patients had been established by clinical, endoscopic, histological, and/or radiological criteria. Infection or the presence of parasites was excluded by stool culture and microscopic examination. The disease activity of active UC was determined using a grading scale including clinical and para-clinical variables. Another 29 subjects without prior history of chronic disease, autoimmune disease, cancer or recent infection were included as a healthy control group. Peripheral blood samples were collected from participants for in vitro cell culture and clinical analysis.

2.2. Blood sampling and analyses

Fasting venous blood samples were collected from individual healthy controls and UC patients. A portion of blood was used to isolate peripheral blood mononuclear cells (PBMCs) by density-gradient centrifugation using Ficoll-Paque PREMIUM (GE Healthcare Bio-science, Sweden), and the surplus blood samples were centrifuged for preparing to examine serum IL-21, IgA, IgM, and IgG.

2.3. Flowcytometry: surface antigen staining

PBMCs from UC patients and healthy controls were harvested and stained in duplicate for CD45-FITC, CD3-ECD, CD8-PE, CD4-FITC, CD19-PC5, CD38-FITC, CD27-PC7, CD86-PE (Beckman Coulter, Brea, CA), CXCR5-PC5 and ICOS-PE (eBioscience, San Diego, CA) at room temperature for 30min. After being washed with PBS, the cells were characterized by flowcytometry analysis using the Beckman Coulter Cytomics FC500 (Beckman Coulter). Cells stained with separate antibodies were defined as certain TH₁ cells (CD4⁺CXCR5⁺TH₁ cells and CD4⁺CXCR5⁺ICOS⁺TH₁ cells) and subsets of B cells (CD38⁺CD19⁺B cells, CD86⁺CD19⁺B cells and CD27⁺CD19⁺ B cells). Data were analysed with a CXP Analysis Cytometer (Beckman Coulter).

2.4. IL-17A intracellular staining

Briefly, PBMC were resuspended in RPMI-1640 medium (Biological Industries, Kibbutz Beit Haemek, Israel) supplemented with 10% heat-inactivated foetal calf serum (Biological Industries) and incubated with phorbol 12-myristate 13-acetate (PMA) (50 ng/mL) and ionomycin (1 mg/mL, Sigma-Aldrich) for 4 hours in the presence of brefeldin A (10 μg/mL, BFA, BD Biosciences, San Jose, CA). Next, the TH₁ cell subset was incubated with the CD3-ECD and CD4-FITC antibodies. After fixation and permeabilization, cells were stained with PC5-conjugated anti-IL-17A (eBioscience).

2.5. Enzyme-linked immunosorbent assay (ELISA) for measurement of serum IL-21

The concentration of serum IL-21 in individual UC patients and HC was determined by ELISA using a human IL-21 ELISA kit (eBioscience) in accordance with the manufacturer’s instructions. Individual serum at 1:4 dilutions were subjected to ELISA, and the concentrations of serum IL-21 in individual samples were calculated according to the standard curve established using the recombinant IL-21 provided.

2.6. Scattering nephelometry for measurement of serum IgA, IgM, and IgG

The concentrations of serum IgA, IgM, and IgG in individual UC patients and HC were examined by scattering nephelometry using an IMMAGE800 biochemical analyzer and matched reagents (Beckman Coulter) in accordance with the manufacturer’s instructions.

2.7. Statistical analysis

Statistical analyses were performed by the GraphPad Prism 6.0 software (La Jolla, CA). The data are expressed as median and range unless specified. The difference between two groups was analysed by the Mann–Whitney U test. The relationship between variables was evaluated by Pearson’s rank correlation test. A two-sided P value of <.05 was considered statistically significant.

3. Results

3.1. Patient characteristics

To assess the potential role of TH₁ cells in the pathogenesis of UC, 31 Chinese patients with UC before treatment and 29 sex- and age-matched healthy controls were recruited from our hospital. The diagnosis and Mayo score of 31 untreated UC patients had been established by clinical, endoscopic, histological, and/or radiological criteria. Infection or the presence of parasites was excluded by stool culture and microscopic examination. The disease activity of active UC was determined using a grading scale including clinical and para-clinical variables. The difference between two groups was analysed by the Mann–Whitney U test. The relationship between variables was evaluated by Pearson’s rank correlation test. A two-sided P value of <.05 was considered statistically significant.

| Parameters | HC (n=31) | UC (n=31) |
|------------|-----------|-----------|
| Age, years | 49 (19–73) | 51 (21–70) |
| female/male | 10/19 | 12/19 |
| CRP, mg/L | 1.3 (0.1–2.6) | 10.6 (1.9–20.2) * |
| ESR, mm/h | 6 (1–12) | 38 (12–135) |
| IgA, g/L | 5.6 (0.5–8.9) | 5.3 (0.7–9.8) |
| IgM, g/L | 13.3 (7.6–20.1) | 35.2 (19.7–73.1) * |
| IgG, g/L | 2.5 (0.5–3.8) | 2.2 (0.3–4.3) |
| Mayo score | NA | 7 (4–12) |
| WBC, 10⁹/L | 6.82 (5.01–9.28) | 6.97 (4.43–11.87) |
| LYMPH, 10⁹/L | 1.75 (0.63–2.89) | 1.86 (0.73–3.41) |

Data are expressed as median (range). CRP = C-reactive protein, ESR = erythrocyte sedimentation rate, HC = healthy controls, NA = not available, UC = ulcerative colitis, WBC = white blood cell count.

* P < .05 vs HC.
Figure 1. Flow cytometry analysis of T_{HJ} and T_{HJ}17 cells. (A) Flow cytometry analysis and (B–D) quantitative analysis. Data shown are representative dot plots or are expressed as the mean percentage of B cells of individual subjects. The difference between the two groups was analysed by the Mann–Whitney U nonparametric test. The horizontal lines represent the median values.
age-matched healthy controls (HCs) were recruited. Comparing the demographic and clinical characteristics of the groups, there was no significant difference in the concentration of serum IgA and IgM, or in the number of white blood cells (WBC) or lymphocytes (LYM), between these 2 groups. As expected, the concentrations of serum C-reactive protein (CRP) and IgG and the erythrocyte sedimentation rate (ESR) were significantly higher in the UC patients than those in the HCs (Table 1), suggesting that those patients were in a state of immune imbalance.

3.2. Increased proportions of circulating TFH and TH17 cells in UC patients

The numbers of TFH cells and TH17 cells were analysed by flow cytometry (Fig. 1A). As shown in Figure 1B to D, the numbers of TFH cells were significantly higher in the UC patients than those in the HCs (Table 1, \( P < 0.01 \)), suggesting that those patients were in a state of immune imbalance.

3.3. Elevated level of serum IL-21 is correlated to TFH cells in UC patients

To explore the correlation between the level of IL-21 and the number of T cell subsets in UC, we detected their serum concentrations via ELISA, and correlation analysis was performed with Pearson’s rank correlation. The level of IL-21 was significantly higher in UC patients than that in HCs (\( P < 0.01 \), Fig. 2A). There was no correlation between the level of IL-21 and the CD4+CXCR5+ TFH cell proportion (data not shown). Interestingly, we observed a positive correlation between the level of IL-21 and the percentage of CD4+CXCR5+ICOS+ TFH cells in UC patients (\( r = 0.6130 \), Fig. 2C) but no correlation between the level of IL-21 and the percentage of CD4+IL-17A+ TH17 cells (\( r = 0.0990 \), Fig. 2B). Our data indicate that IL-21 may be predominantly secreted by CD4+CXCR5+ICOS+ TFH cells in UC patients, and this TFH subset and IL-21 may participate in the development of UC.

3.4. Aberrant frequencies of different subsets of B cells in UC patients

We next characterized the frequencies of different stages of B cells by flow cytometry (Fig. 3A) to assess the impact of B cells in the pathogenic process of UC. The percentages of CD38+CD19+ B cells and CD86+CD19+ B cells in the CD19+ B cell population of the UC patients were significantly higher than those in the HCs (\( P < 0.01 \), Fig. 3B and C). Interestingly, the percentage of CD27+CD19+ B cells in the UC patients was reduced compared to that in the healthy controls (\( P < 0.01 \), Fig. 3D). These data indicate that different subpopulations of B cells may contribute to the pathogenesis in UC patients.

3.5. The relationship between TFH cells and B cell subsets in patients with UC

TFH cells can provide help for B cells by secreting cytokines and stimulating their surface molecules.\(^7,9\) We found that the percentage of CD38+CD19+ B cells in the CD19+ B cell population was positively correlated with the percentage of CD4+CXCR5+ICOS+ TFH cells in the CD4+ TFH cell population of UC patients (\( r = 0.6188 \), Fig. 4A), and the percentage of CD86+CD19+ B cells was positively correlated with the percentage of CD4+CXCR5+ICOS+ TFH cells in UC patients (\( r = 0.4973 \), Fig. 4C). The percentage of CD86+CD19+ B cells was negatively correlated with that of CD4+CXCR5+ICOS+ TFH cells in UC patients (\( r = -0.4674 \), Fig. 4B).

3.6. The relationship between CD4+CXCR5+ICOS+ TFH cells and clinicopathologic parameters of UC patients

Having validated the relationship between TFH cells and the clinical-pathological features of UC patients, we examined the correlations of abnormal clinical laboratory parameters with the number of TFH cells in UC patients. As shown in Figure 5, the concentrations of serum CRP and IgG and the ESR of UC patients were significantly increased compared to those of the HCs (\( P < 0.001 \), Fig. 5A, B, and E). No significant difference was found in the concentration of serum IgA (\( P = 0.790 \), Fig. 5C) or IgM between groups (\( P = 0.5245 \), Fig. 5D). Importantly, compared
Figure 3. Flow cytometry analysis of B cell subsets. (A) Flow cytometry analysis and (B–D) quantitative analysis. Data shown are representative dot plots or are expressed as the mean percentage of B cells of individual subjects.
to that of healthy controls, in patients with UC, the frequency of CD4+CXCR5+ICOS+ TFH cells was significantly correlated with the Mayo score ($P < .0001$, $r = 0.7388$, Fig. 5F) and with the concentrations of serum CRP ($P = .0036$, $r = 0.5076$, Fig. 5G) and IgG ($P = .0245$, $r = 0.4032$, Fig. 5H). These results indicate that a change in the number of CD4+CXCR5+ICOS+ TFH cells in UC patients may have potential as a biomarker to evaluate the severity and prognosis of the disease.

4. Discussion

Increasing evidence shows that the pathogenesis of IBD is associated with immunological abnormalities.\[^{14,5,18}\] TFH cells, as a specific subset of CD4+ T helper cells, play an important role in immune balance.\[^{11}\] TFH cells are involved in the pathogenesis of common autoimmune diseases;\[^{15}\] however, study about TFH cells in UC disease is lacking. In the present study, we found that TFH cells and T_{H17} cells were significantly more abundant in the peripheral blood of UC patients than in the HCs. The data suggest TFH cells and T_{H17} cells may take part in the development of UC.

In addition, TFH cells express high levels of CXCR5, which provides essential help for B cells to produce antibodies and for GCs to produce plasma and memory B cells.\[^{9,19}\] We found that levels of CD4+CXCR5+ TFH cells were significantly elevated in the blood of UC patients, but there was no correlation with the level of IL-21. ICOS is expressed in activated TFH cells, which stimulates the differentiation of activated TFH cells through enhanced IL-21 expression and facilitates B cell antibody production.\[^{12}\] ICOS deletion leads to a profound decrease in memory B cell formation and to a switched antibody response in humans.\[^{21}\] Our data show that circulating CD4+CXCR5+ICOS+ TFH cell and serum IgG levels were higher in UC patients than those in HCs, and a linear positive correlation existed between them, which indicated that ICOS may stimulate B cells to produce IgG to induce the development of UC.

IL-21 is produced mostly by activated CD4+ T cells and controls the differentiation and functional activity of effector TFH

---

**Figure 4.** Correlation analysis between the percentages of TFH cells and B cell subpopulations. (A and C) The percentages of CD8+CD19+B cells and CD8+CD19+B cells were positively correlated with CD4+CXCR5+ICOS+ TFH cells. (B) Negative correlation between the percentages of CD8+CD19+B cells and CD4+CXCR5+ICOS+TFH cells.

**Figure 5.** Comparison of clinical parameters in UC patients versus HCs. TFH cell proportion was significantly correlated with Mayo score and the concentrations of CRP and IgG. (A–E) Quantitative analysis of clinical-pathological features. (F–H) Correlation analysis. The Mayo clinical score and the concentrations of serum CRP and IgG were positively correlated with the percentage of CD4+CXCR5+ICOS+ TFH cells.
whereas a high level of IL–21 triggers the inflammatory pathway and promotes tissue damage in some autoimmune diseases. A study by Ge et al. reported that elevated intracellular IL–21 was correlated to the T<sub>H</sub>17 cell proportion in UC patients, suggesting that IL–21 is mainly produced by T<sub>H</sub>17 cells in UC. Nevertheless, our results demonstrate that the IL–21 level was significantly higher in the UC patients than in the HCs, and no correlation was found between serum IL–21 levels and T<sub>H</sub>17 cells in UC patients, while a significant positive correlation between IL–21 and CD4<sup>+</sup>CXCR5<sup>+</sup>ICOS<sup>+</sup> T<sub>FH</sub> cells was observed. Yu et al. reported elevated levels of T<sub>FH</sub> cells and IL–21 in tissues of UC patients and that IL–21-deficient mice were resistant to dextra sulfate sodium (DSS)-induced colitis and produced fewer T<sub>FH</sub> cells. In combination with our data, these results indicate CD4<sup>+</sup>CXCR5<sup>+</sup>ICOS<sup>+</sup> T<sub>FH</sub> cells may be more closely related to the level of IL–21 than to other IL–21-synthesizing cells, and the secretion of IL–21 could be mainly through T<sub>FH</sub> cells in UC patients. Certainly, in this regard, the main source of IL–21 in the UC pathogenic process necessitates further investigation, and more research is required to reveal the underlying mechanism of interaction between T<sub>FH</sub> cells and IL–21 in UC.

A dysregulated frequency of B cell subsets has been implicated in UC, but the precise mechanism remains unclarified. There is general agreement that activated B cells highly express the CD86 costimulatory molecule, and CD86<sup>+</sup> B cells can differentiate into CD38<sup>+</sup> plasma B cells and then produce antibodies, such as IgM, IgG and IgA. Memory B cells express CD27 and can rapidly respond to antigens and generate immunoglobulin during secondary immune responses. In this study, the levels of circulating CD86<sup>+</sup>CD19<sup>+</sup>activated B cells and CD38<sup>+</sup>CD19<sup>+</sup> plasma B cells in UC patients were significantly higher than those in HCs, and levels of peripheral blood CD27<sup>+</sup>CD19<sup>+</sup> memory B cells in UC patients were reduced compared to those of healthy controls. These data are consistent with previous studies, suggesting that inflammation may promote the development and redistribution of these three subsets of B cells. Alternatively, memory B cells may not play a major role in the pathogenesis of UC. Furthermore, through correlation analysis between T<sub>FH</sub> cells and B cell subsets, we found that the proportions of activated B cells and plasma B cells were positively correlated that of T<sub>FH</sub> cells and that the proportion of memory B cells was negatively correlated with that of T<sub>FH</sub> cells. The basal level of IgG is highly dependent on T<sub>FH</sub> cells, and IgG is reduced markedly in the serum of ICOS<sup>−</sup> mice. Similarly, we found that elevated serum IgG was correlated with the proportion of CD4<sup>+</sup>CXCR5<sup>+</sup>ICOS<sup>+</sup> T<sub>FH</sub> cells. These findings indicate that T<sub>FH</sub> cells may represent a better biomarker to assess the dysregulation of B cell response in UC.

CRP is a nonspecific marker of systemic inflammation. A high level of CRP has been observed in IBD. We found that elevated CRP was positively correlated with elevated T<sub>FH</sub> cells in UC patients, implying that the T<sub>FH</sub> cells may have the potential to be a specific marker to estimate the inflammation degree of UC patients. Furthermore, the Mayo score, as a common disease activity index, provides a unified and standard assessment for the severity of UC, including stool frequency, rectal bleeding, mucosal appearance and physician rating of disease activity. However, measuring the Mayo score requires invasive examination and specialized calculation, which is subjective and slightly inaccurate. Our present study found that the Mayo score was well correlated with T<sub>FH</sub> cell proportion, suggesting that T<sub>FH</sub> cell percentage may have potential as a noninvasive biomarker to evaluate the activity of UC. Much more exploration is required to verify this hypothesis. Collectively, our work demonstrates that circulating T<sub>FH</sub> cells, activated B cells and plasma B cells may participate in the pathogenesis and development of UC, and IL–21 may be a crucial cytokine in the dysimmunity of UC. In UC, the level of IL–21 was strongly correlated with the level of T<sub>FH</sub> cells, but not with T<sub>H</sub>17 cells. T<sub>FH</sub> cells might become a novel noninvasive biomarker to assess immune state and the disease activity of UC. Further evidence on the mechanism and aetiology of UC awaits further study.

Acknowledgments

We thank all participants in this study.

Author contributions

Guohui Xue helped conceive the project. Yao Zhong and Guohui Xue performed the experiments, analysed the data and wrote the manuscript. Nanjin Zhou and Xueli Chen evaluated all the results and helped with the project. Lin Hua, Meijun Zhong, Xiaofeng Liu and Guohui Xue selected the patients, collected the samples and characterized the study cohort. Finally, all authors revised the manuscript. All authors obtained permission to acknowledge all those mentioned in the Acknowledgements.

Conceptualization: Nanjin Zhou, Dian Gao.

Data curation: Nanjin Zhou, Guohui Xue, Dian Gao.

Formal analysis: Yao Zhong, Lin Hua.

Funding acquisition: Guohui Xue, Lin Hua.

Investigation: Yao Zhong, Meijun Zhong, Xiaofeng Liu, Xueli Chen.

Methodology: Yao Zhong, Lin Hua, Xueli Chen.

Project administration: Nanjin Zhou, Guohui Xue.

Resources: Meijun Zhong, Xiaofeng Liu.

Software: Yao Zhong.

Supervision: Nanjin Zhou, Dian Gao.

Validation: Nanjin Zhou, Dian Gao.

Visualization: Nanjin Zhou, Dian Gao.

Writing – original draft: Guohui Xue, Yao Zhong.

Writing – review & editing: Guohui Xue, Yao Zhong, Meijun Zhong, Xiaofeng Liu, Xueli Chen.

References

1. Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature 2008;454:43–44.
2. Gupta RB, Harpaz N, Izkowitz S, et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology 2007;133:1099–103. quiz 340–1.
3. Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet (London, England) 2007;369:1627–40.
4. Geremia A, Biancheri P, Allan P, et al. Innate and adaptive immunity in inflammatory bowel disease. Autoimmun Rev 2014;13:5–10.
5. Park JH, Peyrin-Biroulet L, Eisenhart M, et al. IBD immunopathogenesis: a comprehensive review of inflammatory molecules. Autoimmun Rev 2017;16:416–26.
6. O’Suor JJ, Paul WE. Mechanism underlying lineage commitment and plasticity of helper CD4<sup>+</sup> T cells. Science (New York, NY) 2010;327:1098–102.
7. Crouty S. A brief history of T cell help to B cells. Nat Rev Immunol 2015;15:185–9.
8. 2017;Jann<sup>+</sup> C, Loetsch C, King C. Cytokine expression by T follicular helper cells. Methods in molecular biology (Clifton, NJ) 2016;1625:95–103.
9. Brentfeld D, Ohl L, Kremmer E, et al. Follicular B helper T cells express CXCL13, chemokine receptor 5, localize to B cell follicles, and support immunoglobulin production. J Exp Med 2000;192:1545–52.
10. Chitnova T, Tangye SG, Newton R, et al. T follicular helper cells express a distinctive transcriptional profile, reflecting their role as non-Th1/Th2 effector cells that provide help for B cells. J Immunol (Baltimore, MD: 1950) 2004;173:68–78.
Crotty S. Follicular helper CD4 T cells (TFH). Ann Rev Immunol 2011;29:621–63.

Choi YS, Kageyama R, Eto D, et al. ICOS receptor instructs T follicular helper cell versus effector cell differentiation via induction of the transcriptional repressor Bcl6. Immunity 2011;34:932–46.

Reinhardt RL, Liang HE, Locksley RM. Cytokine-secreting follicular T cells shape the antibody repertoire. Nat Immunol 2009;10:388–93.

Monteleone G, Pallone F, Macdonald TT. Interleukin-21 (IL-21)-mediated pathways in T cell-mediated disease. Cytokine Growth Factor Rev 2009;20:185–91.

Tangye SG, Ma CS, Brink R, et al. The good, the bad and the ugly—TFH cells in human health and disease. Nat Rev Immunol 2013;13:412–26.

Spolski R, Leonard WJ. The Yin and Yang of interleukin-21 in allergy, autoimmunity and cancer. Curr Opin Immunol 2008;20:295–301.

Monteleone G, Monteleone I, Fina D, et al. Interleukin-21 enhances T-helper cell type I signaling and interferon-gamma production in Crohn’s disease. Gastroenterology 2005;128:687–94.

Loddo I, Romano C. Inflammatory bowel disease: genetics, epigenetics, and pathogenesis. Front Immunol 2015;6:551.

Schaezli P, Willmann K, Lang AB, et al. CXCR chemokine receptor 5 expression defines follicular homing T cells with B cell helper function. J Exp Med 2000;192:1553–62.

McAdam AJ, Greenwald RJ, Levin MA, et al. ICOS is critical for CD40-mediated antibody class switching. Nature 2001;409:102–5.

Bossaller L, Burger J, Draeger R, et al. ICOS deficiency is associated with a severe reduction of CXCR5+CD4 germinal center Th cells. J Immunol (Baltimore, MD: 1950) 2006;177:4927–32.

He Z, Jin L, Liu ZF, et al. Elevated serum levels of interleukin 21 are associated with disease severity in patients with psoriasis. Brit J Dermatol 2012;167:191–3.

Sglunda O, Mann HF, Hulejova H, et al. Decrease in serum interleukin-21 levels is associated with disease activity improvement in patients with recent-onset rheumatoid arthritis. Physiol Res 2014;63:475–81.

Zhang J, Zeng H, Ren M, et al. Interleukin-21 is associated with disease activity in patients with Graves’ disease. Endocrine 2014;46:539–48.

Guan LJ, Wang X, Meng S, et al. Increased IL-21/IL-21R expression and its proinflammatory effects in autoimmune thyroid disease. Cytokine 2015;72:160–5.

Ge J, Zhang X, Liu J, et al. Elevated expression of interleukin-21 and its correlation to T-cell subpopulation in patients with ulcerative colitis. Central-European J Immunol 2015;40:331–6.

Yu J, He S, Liu P, et al. Interleukin21 promotes the development of ulcerative colitis and regulates the proliferation and secretion of follicular T helper cells in the colitis microenvironnent. Mol Med Rep 2015;11:1049–56.

Wang X, Jiang Y, Zhu Y, et al. Circulating memory B cells and plasmablasts are associated with the levels of serum immunoglobulin in patients with ulcerative colitis. J Cell Mol Med 2016;20:804–14.

Grusby MJ, Glimcher LH. Immune responses in MHC class II-deficient mice. Ann Rev Immunol 1995;13:417–35.

Dong C, Juedes AE, Temann UA, et al. ICOS co-stimulatory receptor is essential for T-cell activation and function. Nature 2001;409:97–101.

Liu S, Ren J, Xia Q, et al. Preliminary case-control study to evaluate diagnostic values of C-reactive protein and erythrocyte sedimentation rate in differentiating active Crohn’s disease from intestinal lymphoma, intestinal tuberculosis and Behcet’s syndrome. Am J Med Sci 2013;346:467–72.